Skip to main content
IX BIOPHARMA LTD. logo

IX BIOPHARMA LTD. — Investor Relations & Filings

Ticker · 42C ISIN · SG1BD9000009 SGX Manufacturing
Filings indexed 37 across all filing types
Latest filing 2026-05-12 Share Issue/Capital Cha…
Country SG Singapore
Listing SGX 42C

About IX BIOPHARMA LTD.

https://www.ixbiopharma.com/

IX Biopharma Ltd. is a specialty pharmaceutical and nutraceutical company focused on developing and commercializing innovative therapies. Leveraging its proprietary WaferiX sublingual drug delivery technology, the company aims to improve the quality of life for patients with pain, chronic diseases, and debilitating conditions, particularly those affecting the central nervous system. A key product is Wafermine, a sublingual ketamine wafer designed for rapid, non-opioid relief of acute moderate to severe pain. The company was recently awarded a US$41 million U.S. government contract to fund Wafermine's Phase 3 clinical development and secure FDA Emergency Use Authorization. Additionally, iX Biopharma offers nutraceutical products, such as a sublingual NAD+ wafer for cellular energy production.

Recent filings

Filing Released Lang Actions
Equity Listing - Ordinary Shares::Issue and Allotment of Shares Pursuant to Exercise of Warrants
Share Issue/Capital Change Classification · 87% confidence The document is an announcement that the company has issued and allotted new ordinary shares pursuant to the exercise of warrants, describing the number of new shares issued, the exercise price, updated share count, and outstanding warrants. This is a notice of a share issue/capital change. Therefore, it fits the “Share Issue/Capital Change” category (Code: SHA).
2026-05-12 English
Equity Listing - Ordinary Shares::Issue and Allotment of Shares Pursuant to Exercise of Warrants
Share Issue/Capital Change Classification · 90% confidence The document is a corporate announcement by iX Biopharma Ltd’s Board describing the allotment and issuance of new ordinary shares following the exercise of warrants. It details the number of shares issued, exercise price, outstanding warrants, and future listing date. This clearly constitutes a change in capital structure via new share issuance. The appropriate category is Share Issue/Capital Change (SHA).
2026-05-06 English
Equity Listing - Ordinary Shares::Issue and Allotment of Shares Pursuant to Exercise of Warrants
Share Issue/Capital Change Classification · 90% confidence The document is an announcement by the Board of Directors describing the allotment and issuance of new ordinary shares upon exercise of warrants, detailing the number of shares issued, exercise price, post-allotment share count and listing timing. This is a classic capital change/share issue notice rather than a full financial report, earnings release, management discussion, or regulatory filing regarding legal proceedings. Therefore, it fits the Share Issue/Capital Change category.
2026-04-28 English
Equity Listing - Ordinary Shares::Issue and Allotment of Shares Pursuant to Exercise of Warrants
Regulatory Filings
2026-04-23 English
Extraordinary/ Special General Meeting::Voluntary
Regulatory Filings
2026-04-23 English
REPL::Extraordinary/ Special General Meeting::Voluntary
Regulatory Filings
2026-04-23 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.